Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × pCR Rate × Epirubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 145 Stomach Neoplasms 22 Triple Negative Breast Neoplasms 21 Inflammatory Breast Neoplasms 14 Carcinoma, Hepatocellular 13 Esophageal Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 7 Neoplasms 6 Pancreatic Neoplasms 5 Urinary Bladder Neoplasms 4 Adenocarcinoma Of Esophagus 4 Testicular Neoplasms 3 Sarcoma 3 Primary Breast Cancer 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Non-Muscle Invasive Bladder Neoplasms 3 Liver Neoplasms 3 Gallbladder Neoplasms 3 Carcinoma, Ductal, Breast 3 Breast Neoplasms, Male 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Recurrence 2 Pathologic Complete Response 2 Neoplastic Cells, Circulating 2 Neoplasms, Germ Cell and Embryonal 2 HER2-negative Breast Cancer 2 Breast Diseases 2 pCR Rate 1 Women With Primary Breast Cancer 1 Wilms Tumor 1

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡